Details of the Drug

General Information of Drug (ID: DMCNTFW)

Drug Name
Ad-RTS-hIL-12
Indication
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 2 [1]
Melanoma 2C30 Phase 2 [2]
Recurrent glioblastoma 2A00.00 Phase 2 [3]
Malignant glioma 2A00.0 Phase 1 [4]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
D90UZW
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukine 12 (IL-12) TTG68FB IL12A_HUMAN ; IL12B_HUMAN Replacement [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04006119) Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma. U.S. National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033476)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Ziopharm Oncology.